Description

The blood brain barrier (BBB) and the blood cerebrospinal fluid barrier (BCSFB) preclude, under healthy conditions, the free exchange of biologicals between blood and brain. These barriers are of vital importance but severely hamper the delivery of drugs targeting central nervous system (CNS) related disorders or brain tumors. Promising strategies to cross the BBB/BCSFB, include drug delivery by means of targeting to the BBB/BCSFB endothelium, followed by effective transport of the delivery system across the BBB/BCSFB and subsequent release at the brain. In this process, known as receptor mediated transcytosis (RMT), specific receptors responsible for blood-to-brain delivery of nutrients are targeted using affinity binders. Proof of principle for RMT has been generated using antibodies targeting a BBB transporter, but further development has halted due to target-specific safety concerns.
We propose two pioneering and unbiased methods to identify new, safer and more efficient RMT targets for both BBB and BCSFB. Our innovative experimental design will result in the discovery of novel, RMT-mediating single-chain antibodies (VHHs) that we will further develop into efficient BBB/BCSFB shuttling moieties
AcronymFWOSBO23
StatusActive
Effective start/end date1/01/1831/12/21

    Flemish discipline codes

  • Pharmacology not elsewhere classified

    Research areas

  • Brain-derived Neurotrophic Factor

ID: 36020325